Stegmann Systems

What Stegmann Systems does

Stegmann Systems GmbH is a privately held German software company headquartered in Rodgau (near Frankfurt am Main), founded by Dr. Ralf Stegmann. The company employs approximately 50 people and has been developing specialized database software solutions for more than 25 years. It is founder-controlled, with no disclosed institutional investors and no venture funding history; financing is limited to a WIBank HessenFonds Innovation Loan received in October 2025.

The company operates three core software products that share an underlying in-house database platform. PLA 3.0 is biostatistical software for the analysis of biological assays (immunoassays, ELISA, quantitative response assays, dose-response analysis), with explicit support for USP <1032> methodology, FDA/EMA documentation, and method lifecycle management; the company states it is used by virtually all TOP 100 global pharmaceutical and biotech companies. APS is database software for categorizing, managing, networking, and publishing complex datasets in museums, digital archives, and scientific collections. Lageboard is a cloud-based application for automated situation assessment in crisis management teams, serving public-sector civil protection organizations in German districts. Supporting these are the PLA 3.0 Academy learning platform, Knowledge Centers for both PLA and APS, and add-ons such as the Dose-Response Analysis Package 2.0.

Stegmann Systems generates revenue primarily through annual software subscriptions and licenses sold directly to enterprise customers in pharmaceutical/biotech, museum/archive, and government verticals. GTM is enterprise field sales complemented by product-specific websites (bioassay.de, aps-info.de, lageboard.de), industry conference presence (notably CASSS Bioassays), free webinars, and the PLA 3.0 Academy for demand generation and training. Pricing is quote-based and not publicly disclosed. The customer base spans global large-cap pharma (Teva, Fresenius, Ipsen, Johnson & Johnson, Takeda, Astellas, Novo Nordisk), leading European museums (Wallraf-Richartz-Museum, Galleria Florenz), and German public-sector crisis management organizations.

Name

Stegmann Systems

Legal name

Stegmann Systems GmbH

Website

https://stegmannsystems.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

Stegmann Systems GmbH is a privately held German software company (founded by Dr. Ralf Stegmann, ~50 employees, Rodgau) developing PLA 3.0 biostatistics software for bioassay analysis used by top 100 global pharma/biotech, APS database software for museums and archives, and Lageboard for public-sector crisis management.

Ownership category

akta.pro rank

Product category

Scientific and Biostatistical Software

NAICS

Software Publishers (51321)

SIC

Services-Prepackaged Software (7372)

akta.pro industry

PRIMARYHLACAOAO

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)

Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

SECONDARYHLAGAJAI

Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAGAJAM

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

• Bioassay analysis software
• Biostatistical software
• Museum collection management
• Crisis management software
• Pharmaceutical data analysis

Headquarters

HQ city

Rodgau

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software Licenses and Subscriptions (PLA, APS, Lageboard): Stegmann Systems generates revenue primarily through software licensing and subscriptions for its three main products: PLA (biostatistical software for bioassays), APS (museum/archive management software), and Lageboard (cloud-based crisis management application). Products are sold via enterprise direct sales with product-specific websites for demand generation.
2. PLA 3.0 Academy Training and Corporate Learning: Revenue generated from on-demand courses, live workshops, and corporate learning tracks within the PLA 3.0 Academy. Courses culminate in audit-ready certificates. Tiered discounts and expert consulting bonuses are offered for corporate clients.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Stegmann Systems develops and licenses specialized database software through three core products: PLA 3.0 (biostatistical software for analysis of biological assays including immunoassays, ELISA, and quantitative response assays, used by top 100 global pharmaceutical and biotech companies), APS (database software for categorizing, managing, networking, and publishing extensive and complex datasets in museums, digital archives, and scientific collections), and Lageboard (cloud-based application for automated 24/7 situation assessment in public sector crisis management teams). The company offers these through enterprise software licenses with a separate online learning platform (PLA 3.0 Academy).

Product overview

Stegmann Systems is a German software company with approximately 50 employees, developing database software solutions for over 25 years. The company operates three core products: PLA 3.0 (biostatistical software for bioassay analysis used by top 100 pharma/biotech companies), APS (database software for managing museum, archive, and scientific collections), and Lageboard (cloud-based crisis management application). Additionally, the company offers the Dose-Response Analysis Package 2.0 add-on for PLA 3.0. All products are supported by dedicated knowledge centers and the PLA 3.0 Academy learning platform.

Differentiator

Problem solved

Functional benefit

Brands

• PLA 3.0: Biostatistical software for analysis of biological assays including immunoassays, ELISA, and dose-response analysis. Used by pharmaceutical and biotech companies worldwide.
• APS
• Lageboard
• PLA 3.0 Academy

Products and services

• PLA 3.0

Quantifiable outcome

• PLA software is used by all TOP 100 pharmaceutical and biotech companies globally
• +1 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Two partnerships are on record, tiered minor.

• CASSS Bioassays ConferenceminorStrategic or Co-development Partner · 28 April 2026Stegmann Systems participated as an official sponsor and exhibitor at the CASSS Bioassays: Scientific Approaches & Regulatory Strategies conference in Gaithersburg, Maryland (April 28-29, 2026). The conference featured expert speakers, panel discussions, posters, and exhibitors creating opportunities to exchange ideas and explore new solutions.
• rapidmail GmbHminorOthersrapidmail GmbH (Augustinerplatz 2, 79098 Freiburg, Germany) is used as the newsletter service provider for sending the company's newsletter to subscribers.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BMG LABTECH (MARS / Analysis Software): BMG LABTECH provides reader control and data-analysis software for immunoassays and bioassays. Like PLA 3.0, it serves pharma QC labs requiring compliant bioassay analysis, with overlapping capabilities around curve fitting and potency estimation.
• SAS Institute (JMP): JMP is SAS's statistical discovery software widely used for biostatistics, dose-response, and assay analysis in pharma R&D and QC. It is the most direct competitor to PLA 3.0 in pharmaceutical biostatistics, with overlapping functionality for ELISA, immunoassays, and equivalence testing.
• GraphPad (Prism): GraphPad Prism is a widely used statistics package purpose-built for life-science researchers, with strong overlap in dose-response curves, calibration, and bioassay analysis — directly competitive with PLA 3.0's dose-response and equivalence-margin features.
• Molecular Devices (SoftMax Pro): SoftMax Pro is instrument-vendor software for analyzing data from microplate readers used in ELISA and immunoassays. It overlaps with PLA 3.0 in regulated bioassay data reduction and is commonly seen as a complementary or competing tool in pharma QC labs.
• Axiell (Museum Collections): Axiell is a leading provider of collection management systems for museums, galleries, and archives, directly comparable to Stegmann Systems' APS product in target customers, functional scope, and enterprise GTM.
• Gallery Systems (TMS): The Museum System (TMS) by Gallery Systems is a widely deployed museum collection management platform. It competes directly with APS for museum and digital-archive customers managing complex object and dataset catalogs.

Broad incumbents

• Dassault Systèmes BIOVIA: BIOVIA offers a broad scientific software suite spanning lab informatics, quality, and biologics development. It competes indirectly with PLA 3.0 by offering enterprise-wide platforms that can subsume specialized bioassay workflows within larger pharma R&D/QC stacks.
• Thermo Fisher Scientific (Lab Software): Thermo Fisher offers a broad range of lab instruments and accompanying analysis software for bioassays, ELISA, and QC workflows. It overlaps with PLA 3.0's end-user base and competes as part of a wider instrument-and-software portfolio rather than as a standalone analytics product.
• LabWare (LIMS): LabWare is a leading LIMS/ELN platform serving regulated pharma labs, with adjacencies to PLA 3.0 in bioassay and QC workflows. It competes indirectly by offering broader lab informatics that can integrate or replace specialized bioassay tools.

Emerging players

• Dotmatics: Dotmatics provides cloud-native scientific R&D informatics for pharma and biotech, including assay data and biostatistics capabilities. It represents an emerging cloud-first alternative to PLA 3.0 for next-generation pharma informatics buyers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stegmann-systems-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stegmann Systems